DARE stock: buy or sell?
August 22nd, 2019
Daré Bioscience, Inc. develops and commercializes product for women's reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.
Should I buy DARE stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Dare Bioscience stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Dare Bioscience stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we detected 2 ratings published for DARE stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
DARE stock analysis
Shares of Dare Bioscience skyrocketed a super good 5.06% and closed at $0.83.
Dare Bioscience skyrocketed a super good 5.06% and closed at $0.83. Since price and SMA200d lines crossed down on May, DARE fell $-0.18 per share (-17.82%). DARE is retaking the upward trend marking a new rising bottom heading to break out over $0.99.
Dare Bioscience shares skyrocketed 7.79% this week, ending at $0.83. Early August DARE plummed a hair-raising -6.67% in just one week.
Since price and 40-weeks moving average lines crossed down early May, DARE fell $-0.15 per share (-15.31%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.
DARE stock price history
DARE IPO was on April 10th, 2014 at $71.00 per share1. Since then, DARE stock lost a -98.80%, with a yearly average of -19.80%.
1: Adjusted price after possible price splits or reverse-splits.
DARE stock historical price chart
DARE stock reached 52-week highs on March at $3.25, and all-time highs 2015-03-19 with a price of 108.7.
DARE stock price target is $3.00How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price prediction for Dare Bioscience stock was posted in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last April, when Dare Bioscience posted its last earnings report, it . As soon as we get its actual EPS from the earnings report, we will extend this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2016, Dare Bioscience annual turnover climbed an outstanding 857.50% to $0.77 M dollars from $0.08 marked in 2014. When comparing 2016 vs 2014, likewise, profit margin (that is, the net income divided by revenues) rocketed a 24,046.30% to -5,131.20%.
|2013||$6.00 M||-||$0.00 M0.0%||-|
|2014||$0.08 M||-98.67%||$-23.34 M-29177.5%||0.00%|
|2016||$0.77 M||857.50%||$-39.31 M-5131.2%||68.39%|
Quarterly financial resultsReported quarter income marked $-2.92 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Dare Bioscience sales marked a neutral movement and remained constant a nan%. Looking back to recent quarterly results, Dare Bioscience posted 7 positive quarters in a row.
|2017-Q1||$1,192.00 M||-||$0.00 M0.0%||-|
|2017-Q2||$642.00 M||-46.14%||$0.00 M0.0%||0.00%|
Dare Bioscience ownershipWhen you are planning to buy a stock, it's always worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Dare Bioscience, 16.92% of all outstanding shares are owned by its staff.
In case of Dare Bioscience stock, 8.11% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for DARE stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$0.0 M||$67.1 B||$312.2 M||$387.3 M||$1.3 B|
|Total shares||0.0 M||701.0 M||53.0 M||149.5 M||14.3 M|
|Float shares||13.9 M||706.3 M||40.5 M||135.2 M||6.4 M|
|- Institutional holdings (%)||8.1%||77.6%||103.6%||84.5%||97.1%|
|- Insider holdings (%)||16.9%||0.2%||3.0%||1.6%||11.3%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$0.75 - $0.94|
|Average true range||$0.07|
|50d mov avg||$0.80|
|100d mov avg||$0.91|
|200d mov avg||$0.91|
Dare Bioscience performanceTo better understand Dare Bioscience performance you must becnhmark its gains with other related stocks in same sector or industry. In the following table, we compare Dare Bioscience performance to Celgene, Clovis Oncology, ImmunoGen, Madrigal Pharmaceuticals, Nektar, Seattle Genetics and Spectrum Pharmaceuticals: